KPF
XENE icon

K2 Principal Fund’s Xenon Pharmaceuticals XENE Stock Holding History

K2 Principal Fund’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-101,103
Closed -$495K – 378
2018
Q1 		$495K Sell
101,103
-118,440
-54% -$438K 0.03% 264
2017
Q4 		$620K Buy
219,543
+55,033
+33% +$150K 0.04% 223
2017
Q3 		$485K Hold
164,510
– – 0.03% 256
2017
Q2 		$518K Buy
164,510
+47,535
+41% +$186K 0.03% 261
2017
Q1 		$468K Buy
116,975
+59,747
+104% +$470K 0.04% 241
2016
Q4 		$441K Buy
57,228
+42,228
+282% +$339K 0.04% 207
2016
Q3 		$122K Buy
+15,000
New +$116K 0.01% 258

Other funds holding XENE

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

K2 Principal Fund's XENE Position: Q2 2018 in Review

K2 Principal Fund sold out of Xenon Pharmaceuticals (XENE) in Q2 2018, closing a stake of 101,103 shares — an estimated $495K sold.

K2 Principal Fund first reported a position in XENE in Q3 2016 and held it in 7 quarters. The position peaked at $620K in Q4 2017. 42 funds tracked by Wall St. Rank hold XENE as of Q2 2018.

  • K2 Principal Fund reported no remaining Xenon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • K2 Principal Fund sold 101,103 Xenon Pharmaceuticals shares in Q2 2018, an estimated $495K.
  • K2 Principal Fund first reported a position in Xenon Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • K2 Principal Fund's Xenon Pharmaceuticals position peaked at $620K in Q4 2017.
  • 42 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2018.

Based on K2 Principal Fund's 13F filing for Q2 2018, filed 13 Aug 2018.